Panome Bio
Panome Bio is a CLIA-certified multi-omics CRO offering metabolomics, proteomics, transcriptomics, and exposomics services to biopharma, biotech, and academic clients, anchored by its MassID™ deep-learning computational platform and proprietary LC-MS workflows.
- Company typePrivate
- Founded2022
- HeadquartersSt Louis, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Panome Bio does
Panome Bio is a CLIA-certified multi-omics contract research organization (CRO) headquartered in the Cortex Innovation Community in St. Louis, Missouri. Founded in 2022, the company provides liquid chromatography–mass spectrometry (LC/MS)-based services spanning metabolomics, proteomics, transcriptomics, and exposomics to biopharmaceutical companies, biotechnology firms, and academic research institutions engaged in biomarker discovery, mechanism-of-action studies, patient stratification, and clinical-trial support. The portfolio is anchored by Next-Generation Metabolomics® (four complementary LC-MS assays covering polar and lipid metabolites) and Discovery Proteomics (Seer Proteograph XT coupled with a Thermo Fisher Orbitrap Astral mass spectrometer), augmented by specialized offerings such as TissueBridge™ FFPE metabolomics, Global Phosphoproteomics, Targeted Proteomics, PRMT5 Metabolomics Panel, and Discovery and Targeted Exposomics™.
The company's core proprietary technology is MassID™, a cloud-based computational platform that integrates deep learning for peak detection and noise filtering with a 280,000-compound reference database and probability-based FDR-controlled metabolite identification. MassID underpins the Next-Generation Metabolomics® service and feeds an integrated multi-omics analysis platform that interweaves metabolomics, proteomics, and transcriptomics datasets onto shared biochemical networks for pathway-level interpretation. Panome Bio monetizes through project-based, quote-priced CRO engagements with biopharma, biotech, and academic customers, acquired via scientific conference participation (AACR, ASMS, US HUPO, ASCO, Society of Toxicology, EACR, Festival of Biologics), webinars, content marketing, and strategic channel partnerships such as TD2 Oncology. As of early 2026 the company had raised approximately $6M in growth financing (Telegraph Hill Partners, BioGenerator Ventures), obtained CLIA certification, and scaled its multi-omics service menu beyond metabolomics into clinical-grade biomarker workflows.
Panome Bio firmographics
Firmographics- Name
- Panome Bio
- Legal name
- Panome Bio
- Website
- https://panomebio.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Panome Bio is a CLIA-certified multi-omics CRO offering metabolomics, proteomics, transcriptomics, and exposomics services to biopharma, biotech, and academic clients, anchored by its MassID™ deep-learning computational platform and proprietary LC-MS workflows.
- Ownership category
- akta.pro rank
Panome Bio industry classification
Industry- Product category
- Multi-omics Contract Research Services
- NAICS
- Medical Laboratories (621511), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Proteomics & Mass Spectrometry Services (HLAGANAB), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)
Keywords
Where Panome Bio is headquartered
LocationHeadquarters
- HQ city
- St Louis
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Panome Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Contract Research Services (CRO): Panome Bio operates as a CLIA-certified multi-omics contract research organization providing laboratory services to biopharma, biotech, and academic researchers. Services are project-based, with customers submitting samples for analysis. Services are available to biopharma, biotech, and academic partners. Pricing is quote-based.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing for CRO services |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
Panome Bio product offering
Product offeringCore offering
Panome Bio is a CLIA-certified multi-omics contract research organization (CRO) providing metabolomics, proteomics, transcriptomics, and exposomics services to biopharma, biotech, and academic research clients. The company leverages liquid chromatography-mass spectrometry (LC-MS) technology combined with proprietary computational pipelines (MassID™) to deliver untargeted profiling across biofluids, tissues, FFPE samples, and cell cultures, with data turnaround in 4-6 weeks. Services are project-based and quote-priced, supporting biomarker discovery, mechanism of action studies, patient stratification, and clinical trial biomarker analysis.
Product overview
Panome Bio is a multi-omics contract research organization offering a comprehensive portfolio of services built around Next-Generation Metabolomics® and Discovery Proteomics as core platforms. The service portfolio includes specialized metabolomics offerings (Next-Generation Lipidomics®, Metabolic Flux Analysis, PRMT5 Metabolomics Panel, TissueBridge™ FFPE Metabolomics, Microbiome Function Analysis, Cell Surface Membrane Lipidomics) and proteomics services (Discovery Proteomics for Biofluids and Tissues, Targeted Proteomics, Global Phosphoproteomics, Cell Surface Proteomics). Additional offerings include Transcriptomics, Integrated Multi-omics, Cell Surface Multi-omics, and Exposomics (Discovery Exposomics™ and Targeted Exposomics™). MassID™ serves as the proprietary computational identification engine powering Next-Generation Metabolomics®, providing AI-driven metabolite identification with confidence scoring. All services are delivered through a unified workflow with data turnaround in 4-6 weeks.
Differentiator
Problem solved
Functional benefit
Products and services
- Next-Generation Metabolomics®
Companies that use Panome Bio
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Panome Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature8 records
Panome Bio partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- TD2 OncologycorePanome Bio and TD2 Oncology expanded their strategic partnership to provide integrated multi-omics profiling combined with translational and clinical oncology expertise. The collaboration enables researchers to access Panome Bio's capabilities in metabolomics, proteomics, transcriptomics, and exposomics alongside TD2's expertise in evaluating therapeutic candidates in clinically relevant settings. Designed to support biomarker discovery, mechanism-of-action studies, and clinical development including patient selection strategies and biomarker-driven trial design.
- Audubon BioscienceminorPanome Bio and Audubon Bioscience partnered on end-to-end FFPE solutions, combining Panome Bio's TissueBridge FFPE metabolomics service with Audubon Bioscience's sample supply capabilities for comprehensive archived tissue analysis.
- Seer Bio (Centers of Excellence Program)corePanome Bio was added to Seer's Centers of Excellence (COE) Program, recognizing the company's excellence in proteomics analysis using Seer's Proteograph XT platform coupled with the Thermo Fisher Orbitrap Astral mass spectrometer. The COE designation reflects Panome Bio's advanced capabilities in biofluid proteomics.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Panome Bio competitors and assessment
Company assessmentEmerging players
- MOBILion Systems: Emerging separation-science company enabling high-throughput, high-resolution omics measurements. Represents a future technology-input alternative to current LC-MS pipelines Panome Bio depends on.
Direct peers
- Metabolon: Largest dedicated metabolomics CRO, offering untargeted metabolomics and lipidomics services to biopharma and academic clients. Panome Bio directly competes on the same Next-Generation Metabolomics value proposition with its own MassID pipeline.
- SomaLogic: Proteomics platform offering high-plex protein biomarker measurement (SomaScan) to biopharma and academic clients. Overlaps with Panome Bio's biofluid proteomics and biomarker discovery offerings.
- Biocrates Life Sciences: Specialist metabolomics CRO offering targeted and quantitative metabolomics panels (similar to Panome Bio's Targeted Metabolomics) for pharma, clinical research, and academic customers across the same buyer base.
- Olink: Proteomics company providing high-multiplex biomarker discovery and targeted protein panels for translational and clinical research. Competes directly with Panome Bio's discovery and targeted proteomics services.
- Proteome Sciences: Contract proteomics services firm specializing in mass spectrometry-based protein profiling and biomarker discovery for pharma and academic clients — directly comparable CRO model to Panome Bio's proteomics arm.
Broad incumbents
- Eurofins Scientific: Global mega-CRO with significant metabolomics, proteomics, and exposomics service offerings across pharma, food, and environmental end markets. Competes broadly with Panome Bio from a scale and breadth advantage rather than specialization.
- Charles River Laboratories: Large CRO with established discovery, biomarker, and multi-omics service lines serving biopharma. Comparable as a broader-services competitor that can bundle omics into enterprise contracts.
- Bruker: Mass spectrometry and proteomics instrumentation vendor that also offers applications/services in metabolomics and proteomics. Adjacent competitor with overlapping analytical capability but a fundamentally different business model.
Regional players
- BGI Genomics: Asia-headquartered multi-omics service provider with metabolomics, proteomics, and transcriptomics offerings. Overlapping capability but primarily serving Asia-Pacific customers; competes in cross-border biopharma accounts.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Panome Bio social profiles
Digital presencePanome Bio compliance and trust
Trust signalCompliance1 record
Panome Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Panome Bio leadership team
Management profileNumber of profiles
Profiles8 records
Panome Bio funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Panome Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Panome Bio
What does Panome Bio do?
Panome Bio is a CLIA-certified multi-omics contract research organization (CRO) providing metabolomics, proteomics, transcriptomics, and exposomics services to biopharma, biotech, and academic research clients. The company leverages liquid chromatography-mass spectrometry (LC-MS) technology combined with proprietary computational pipelines (MassID™) to deliver untargeted profiling across biofluids, tissues, FFPE samples, and cell cultures, with data turnaround in 4-6 weeks. Services are project-based and quote-priced, supporting biomarker discovery, mechanism of action studies, patient stratification, and clinical trial biomarker analysis.
Is Panome Bio a public or private company?
Panome Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Panome Bio founded?
Panome Bio was founded in 2022. It employs 11 to 50 people.
Where is Panome Bio based?
Panome Bio is headquartered in St Louis, United States, in the North America region.
How does Panome Bio make money?
One revenue line is on record: contract Research Services (CRO).
Who are Panome Bio's main competitors?
MOBILion Systems is listed as an emerging player. Direct peers are Metabolon, SomaLogic, Biocrates Life Sciences, Olink and Proteome Sciences. Broad incumbents are Eurofins Scientific, Charles River Laboratories and Bruker. BGI Genomics is listed as a regional player.
Does Panome Bio have an API?
No public API is recorded for Panome Bio.
What industry is Panome Bio in?
Panome Bio's product category is Multi-omics Contract Research Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGANAB, Proteomics & Mass Spectrometry Services. Its NAICS code is 621511 and its SIC code is 8071.